Source: Health Canada shortage reports · Updated Jul 9, 2026
Some Everolimus products are in shortage in Canada (1 of 11 reported products), while others remain available. Your pharmacy may be able to substitute an unaffected manufacturer.
A medication (mTOR inhibitor) used to prevent transplant rejection and to treat certain cancers.
Products affected
1 / 11
In shortage since
Jan 10, 2024
Reports on file
22
Talk to a pharmacist
Pharmacists can substitute an unaffected manufacturer's version, adjust strengths, and in most provinces adapt or renew a prescription on the spot.
Independent services, not affiliated with rxstat; referral fees may apply. Free options exist depending on your province. In an emergency call 911; free health advice at 811.
Shortage history
Shortage history (red bands = periods in shortage).
Reports by product
The DIN is printed on your prescription label.
Active shortage
TEVA-EVEROLIMUS
2.5MG · TABLET · TEVA CANADA LIMITED
DIN 02463229 · since Jan 10, 2024, est. end Jul 10, 2026 · Disruption of the manufacture of the drug.
Resolved
TEVA-EVEROLIMUS
10MG · TABLET · TEVA CANADA LIMITED
DIN 02463253 · ended Apr 15, 2026 · Disruption of the manufacture of the drug.
Resolved
NAT-EVEROLIMUS
2.5MG · TABLET · NATCO PHARMA (CANADA) INC
DIN 02530090 · ended Jul 3, 2025 · Delay in shipping of the drug.
Resolved
NAT-EVEROLIMUS
10MG · TABLET · NATCO PHARMA (CANADA) INC
DIN 02530120 · ended Jul 3, 2025 · Disruption of the manufacture of the drug.
Resolved
NAT-EVEROLIMUS
5MG · TABLET · NATCO PHARMA (CANADA) INC
DIN 02530104 · ended Jul 3, 2025 · Disruption of the manufacture of the drug.
Resolved
TEVA-EVEROLIMUS
5MG · TABLET · TEVA CANADA LIMITED
DIN 02463237 · ended Jun 18, 2025 · Disruption of the manufacture of the drug.
Resolved
PMS-EVEROLIMUS
5MG · TABLET · PHARMASCIENCE INC
DIN 02504685 · ended Jan 26, 2025 · Disruption of the manufacture of the drug.
Resolved
PMS-EVEROLIMUS
2.5MG · TABLET · PHARMASCIENCE INC
DIN 02504677 · ended Jan 26, 2025 · Disruption of the manufacture of the drug.
Resolved
SANDOZ EVEROLIMUS
2.5MG · TABLET · SANDOZ CANADA INCORPORATED
DIN 02492911 · ended Dec 16, 2024 · Disruption of the manufacture of the drug.
Resolved
SANDOZ EVEROLIMUS
5MG · TABLET · SANDOZ CANADA INCORPORATED
DIN 02492938 · ended Apr 30, 2024 · Requirements related to complying with good manufacturing practices.
Resolved
SANDOZ EVEROLIMUS
2.5MG · TABLET · SANDOZ CANADA INCORPORATED
DIN 02492911 · ended Aug 21, 2023 · Disruption of the manufacture of the drug.
Resolved
PMS-EVEROLIMUS
2.5MG · TABLET · PHARMASCIENCE INC
DIN 02504677 · ended Jun 6, 2023 · Disruption of the manufacture of the drug.
Showing 12 of 22 reports. All reports are on file with Health Canada.
What's happening
Everolimus is currently affected by an active shortage report filed with Health Canada by TEVA CANADA LIMITED.
The reported cause is: disruption of the manufacture of the drug. Manufacturers must report shortages, but end-date estimates are their own projections and often move.
If your usual product is affected, a pharmacist is the fastest route to a solution: they can dispense an unaffected manufacturer's equivalent when one exists, and in most provinces can adapt doses or substitute a therapeutic alternative without a new appointment.
Recent changes
No changes recorded yet.
Common questions
What is Everolimus used for?
A medication (mTOR inhibitor) used to prevent transplant rejection and to treat certain cancers.
When will Everolimus be back in stock in Canada?
Manufacturers have not provided a reliable end date. This page updates automatically as soon as an estimate is filed.
Why is Everolimus in shortage?
See the reports above; manufacturers must state a reason (most commonly manufacturing disruption or a surge in demand) when filing with Health Canada.
What can my pharmacist do about it?
Often quite a lot: substitute an equivalent product from an unaffected manufacturer, adjust quantities, or in most provinces adapt or renew prescriptions on the spot. Call your pharmacy before visiting, and call 811 for free health advice.
Email alerts
Get an email when this drug's status changes. Double opt-in, one-click unsubscribe.
Possible alternatives in the same class
Drugs in the same therapeutic class, best-supplied first. These are not automatic substitutes: only your pharmacist or prescriber can judge whether a switch makes sense for you.
Data reflects reports manufacturers are legally required to file with Health Canada, republished with per-drug aggregation by rxstat. Estimated end dates are supplied by manufacturers and frequently change. This page describes drug supply only and is not medical advice; never stop or switch a medication without speaking to your pharmacist or prescriber.